Ken Griffin Cor Medix Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $53,040 - $83,070	13,000 Added 15.24%	98,300 $425,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.24 $82,614 - $119,144	28,100 Added 49.13%	85,300 $361,000
Q4 2023 Feb 14, 2024	SELL	$3.0 - $4.01 $344,700 - $460,749	-114,900 Reduced 66.76%	57,200 $215,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $258,120 - $319,782	71,700 Added 71.41%	172,100 $636,000
Q2 2023 Aug 14, 2023	SELL	$3.94 - $5.8 $34,672 - $51,040	-8,800 Reduced 8.06%	100,400 $397,000
Q1 2023 May 15, 2023	BUY	$3.22 - $4.61 $56,672 - $81,136	17,600 Added 19.21%	109,200 $452,000
Q4 2022 Feb 14, 2023	BUY	$2.81 - $4.45 $148,930 - $235,850	53,000 Added 137.31%	91,600 $386,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $8,460 - $22,560	-3,000 Reduced 7.21%	38,600 $109,000

107

17.5M

70.5K

358K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $468M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.